NEW YORK (GenomeWeb) – Caris Life Sciences and Threshold Pharmaceuticals announced today that they have partnered to develop a tissue-based assay to predict how pancreatic cancer patients will respond to Threshold’s investigational drug evofosfamide.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.